OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
8406$0.0555

China Oral Industry Group Holdings Ltd

Healthcare Facilities & ServicesVerified

The company's capital structure is characterized by a market price of 0.051 and a market cap of 83.71 million, with a price-to-book ratio of 0.87, indicating that the market value is below the book value of the company's equity. The company's liquidity is assessed as medium, with a current ratio of 2.78, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash is negative after subtracting total debt, which raises concerns about its liquidity position. Profitability metrics show a challenging financial position, with a return on equity of -44.17% and a return on assets of -25.7%, both significantly below the industry median. The company reported a net loss of 42.72 million and an operating loss of 43.07 million, indicating a lack of profitability. The gross profit of 14.13 million is also low relative to its revenue of 167.65 million, suggesting high cost pressures or low pricing power. The company's revenue is not segmented by geographic regions or business lines in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the lack of segment data limits the ability to evaluate the company's diversification and risk profile. The company's growth trajectory is uncertain, as it has reported a net loss and negative operating income. There are no specific numeric deltas provided for the current or next fiscal year, but the company's financial performance suggests a lack of growth. The company's revenue history does not indicate a clear upward or downward trend, but the negative profitability metrics suggest operational challenges. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity constraints. The dilution risk is low, and there are no specific dilution sources or expected timeframes provided in the available data. Recent events or filings are not detailed in the available data, so it is not possible to assess the company's recent performance or strategic direction based on disclosed events or transcripts. The lack of recent event data limits the ability to evaluate the company's current situation and future prospects.

30-day price · 8406-0.01 (-15.0%)
Low$0.05High$0.07Close$0.05As of28 May, 00:00 UTC
Profile
CompanyChina Oral Industry Group Holdings Ltd
Ticker8406.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. China Oral Industry Group Holdings Ltd is engaged in the pharmaceuticals industry, focusing on healthcare facilities and services, and generates revenue primarily through its operations in this sector.

Classification. The company is classified under the Healthcare economic sector, within the Healthcare Services & Equipment business sector, and the Healthcare Facilities & Services industry, with a classification confidence of 0.92.

The company's capital structure is characterized by a market price of 0.051 and a market cap of 83.71 million, with a price-to-book ratio of 0.87, indicating that the market value is below the book value of the company's equity. The company's liquidity is assessed as medium, with a current ratio of 2.78, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash is negative after subtracting total debt, which raises concerns about its liquidity position. Profitability metrics show a challenging financial position, with a return on equity of -44.17% and a return on assets of -25.7%, both significantly below the industry median. The company reported a net loss of 42.72 million and an operating loss of 43.07 million, indicating a lack of profitability. The gross profit of 14.13 million is also low relative to its revenue of 167.65 million, suggesting high cost pressures or low pricing power. The company's revenue is not segmented by geographic regions or business lines in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the lack of segment data limits the ability to evaluate the company's diversification and risk profile. The company's growth trajectory is uncertain, as it has reported a net loss and negative operating income. There are no specific numeric deltas provided for the current or next fiscal year, but the company's financial performance suggests a lack of growth. The company's revenue history does not indicate a clear upward or downward trend, but the negative profitability metrics suggest operational challenges. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity constraints. The dilution risk is low, and there are no specific dilution sources or expected timeframes provided in the available data. Recent events or filings are not detailed in the available data, so it is not possible to assess the company's recent performance or strategic direction based on disclosed events or transcripts. The lack of recent event data limits the ability to evaluate the company's current situation and future prospects.
Key takeaways
  • The company is operating at a loss, with a net income of -42.72 million and an operating income of -43.07 million.
  • The company's market price is 0.051, and its market cap is 83.71 million, with a price-to-book ratio of 0.87.
  • The company's return on equity is -44.17%, and its return on assets is -25.7%, both significantly below the industry median.
  • The company's liquidity is assessed as medium, with a current ratio of 2.78, but it has negative net cash after subtracting total debt.
  • The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
  • The company's risk assessment indicates a medium liquidity risk and a low dilution risk.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$167.6M
Gross profit$14.1M
Operating income-$43.1M
Net income-$42.7M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$166.2M
Total liabilities$69.5M
Total equity$96.7M
Cash & equivalents
Long-term debt$17.6M
Valuation
Market price$0.05
Market cap$83.7M
Enterprise value$101.3M
P/E
Reported non-GAAP P/E
EV/Revenue0.6
EV/Op income
EV/OCF
P/B0.9
P/Tangible book0.9
Tangible book$96.7M
Net cash-$17.6M
Current ratio2.8
Debt/Equity0.2
ROA-25.7%
ROE-44.2%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
Metric8406Activity
Op margin-25.7%7.7% medp25 -2.4% · p75 15.5%bottom quartile
Net margin-25.5%5.9% medp25 -3.8% · p75 12.8%bottom quartile
Gross margin8.4%45.5% medp25 31.1% · p75 62.9%bottom quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity18.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-19 16:50 UTC#0a0fb2ec
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 04:14 UTCJob: 9ecf6190